JP2010529994A5 - - Google Patents

Download PDF

Info

Publication number
JP2010529994A5
JP2010529994A5 JP2010512352A JP2010512352A JP2010529994A5 JP 2010529994 A5 JP2010529994 A5 JP 2010529994A5 JP 2010512352 A JP2010512352 A JP 2010512352A JP 2010512352 A JP2010512352 A JP 2010512352A JP 2010529994 A5 JP2010529994 A5 JP 2010529994A5
Authority
JP
Japan
Prior art keywords
compound
deuterium
hydrogen
independently
enantiomer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2010512352A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010529994A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2008/066730 external-priority patent/WO2008157240A1/en
Publication of JP2010529994A publication Critical patent/JP2010529994A/ja
Publication of JP2010529994A5 publication Critical patent/JP2010529994A5/ja
Pending legal-status Critical Current

Links

JP2010512352A 2007-06-13 2008-06-12 置換ピペラジン Pending JP2010529994A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US94373107P 2007-06-13 2007-06-13
PCT/US2008/066730 WO2008157240A1 (en) 2007-06-13 2008-06-12 Substituted piperazines

Publications (2)

Publication Number Publication Date
JP2010529994A JP2010529994A (ja) 2010-09-02
JP2010529994A5 true JP2010529994A5 (cg-RX-API-DMAC7.html) 2011-07-28

Family

ID=39609397

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010512352A Pending JP2010529994A (ja) 2007-06-13 2008-06-12 置換ピペラジン

Country Status (9)

Country Link
US (2) US20080312247A1 (cg-RX-API-DMAC7.html)
EP (1) EP2155697B1 (cg-RX-API-DMAC7.html)
JP (1) JP2010529994A (cg-RX-API-DMAC7.html)
KR (1) KR20100047190A (cg-RX-API-DMAC7.html)
CN (1) CN101835761A (cg-RX-API-DMAC7.html)
AU (1) AU2008266124A1 (cg-RX-API-DMAC7.html)
CA (1) CA2690379A1 (cg-RX-API-DMAC7.html)
IL (1) IL202666A0 (cg-RX-API-DMAC7.html)
WO (1) WO2008157240A1 (cg-RX-API-DMAC7.html)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2139877B1 (en) * 2007-03-07 2011-05-11 Concert Pharmaceuticals Inc. Deuterated piperazine derivatives as anti-anginal compounds
US20110053968A1 (en) 2009-06-09 2011-03-03 Auspex Pharmaceuticals, Inc. Aminopyrimidine inhibitors of tyrosine kinase
BR112012007137A2 (pt) 2009-09-30 2015-09-15 Harvard College metodos para modulacao da autofagia por meio da modulacao de produtos genicos inibidores da autofagia
CN101811941A (zh) * 2010-03-12 2010-08-25 重庆欣欣向荣精细化工有限公司 邻羟基苯基烷基醚的制备方法
CN102295622A (zh) 2010-06-25 2011-12-28 上海冠杰生物医药科技有限公司 一种雷诺嗪的制备方法
EP2524688B1 (en) * 2011-05-11 2013-05-01 ratiopharm GmbH Composition for modified release comprising ranolazine
WO2012170676A1 (en) * 2011-06-08 2012-12-13 Sti Pharma, Llc Controlled absorption water-soluble pharmaceutically active organic compound formulation for once-daily administration
RU2737434C2 (ru) 2013-03-13 2020-11-30 Форма Терапьютикс, Инк. Новые соединения и композиции для ингибирования fasn
US20160030426A1 (en) * 2013-03-14 2016-02-04 Celgene Avilomics Research, Inc. Heteroaryl compounds and uses thereof
US20160244436A1 (en) * 2013-09-25 2016-08-25 Cortendo Ab (Publ) Novel functionalized 5-(phenoxymethyl)-1,3-dioxane analogs exhibiting cytochrome p450 inhibition and their method of use
KR20160117596A (ko) 2014-02-07 2016-10-10 오스펙스 파마슈티칼스, 인코포레이티드 신규 제약 제제
US10793554B2 (en) 2018-10-29 2020-10-06 Forma Therapeutics, Inc. Solid forms of 4-(2-fluoro-4-(1-methyl-1H-benzo[d]imidazol-5-yl)benzoyl)piperazin-1-yl)(1-hydroxycyclopropyl)methanone
CN116251072B (zh) * 2023-03-14 2023-09-15 郑州大学第一附属医院 一种吲哚布芬片及其制备方法、用途

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4567264A (en) * 1983-05-18 1986-01-28 Syntex (U.S.A.) Inc. Cardioselective aryloxy- and arylthio- hydroxypropylene-piperazinyl acetanilides which affect calcium entry
US6221335B1 (en) * 1994-03-25 2001-04-24 Isotechnika, Inc. Method of using deuterated calcium channel blockers
US6884429B2 (en) * 1997-09-05 2005-04-26 Isotechnika International Inc. Medical devices incorporating deuterated rapamycin for controlled delivery thereof
US6479496B1 (en) * 1998-09-10 2002-11-12 Cv Therapeutics, Inc. Methods for treating angina with ranolazine
US6303607B1 (en) * 1998-09-10 2001-10-16 Cv Therapeutics, Inc. Method for administering a sustained release ranolanolazine formulation
US6440710B1 (en) * 1998-12-10 2002-08-27 The Scripps Research Institute Antibody-catalyzed deuteration, tritiation, dedeuteration or detritiation of carbonyl compounds
US6396062B1 (en) * 1999-12-03 2002-05-28 Cymer, Inc. Portable laser beam monitor
EP1104760B1 (en) * 1999-12-03 2003-03-12 Pfizer Products Inc. Sulfamoylheteroaryl pyrazole compounds as anti-inflammatory/analgesic agents
EP1134290A3 (en) * 2000-03-14 2004-01-02 Pfizer Products Inc. Pharmacophore models for the identification of the CYP2D6 inhibitory potency of selective serotonin reuptake inhibitors
TW200413273A (en) * 2002-11-15 2004-08-01 Wako Pure Chem Ind Ltd Heavy hydrogenation method of heterocyclic rings
WO2006008753A1 (en) * 2004-07-19 2006-01-26 Unichem Laboratories Limited Crystalline and amorphous form of ranolazine and the process for manufacturing them
EP1912947A1 (en) * 2005-07-26 2008-04-23 Nycomed GmbH Isotopically substituted pantoprazole
US20080033011A1 (en) * 2005-07-29 2008-02-07 Concert Pharmaceuticals Inc. Novel benzo[d][1,3]-dioxol derivatives
CN101273024A (zh) * 2005-07-29 2008-09-24 康瑟特制药公司 新颖苯并[d][1,3]-二氧杂环戊烯衍生物
CN101309917B (zh) * 2005-10-06 2013-09-11 奥斯拜客斯制药有限公司 具有增强治疗性质的胃h+,k+-atp酶氘代抑制剂
US7750168B2 (en) * 2006-02-10 2010-07-06 Sigma-Aldrich Co. Stabilized deuteroborane-tetrahydrofuran complex
EP2139877B1 (en) * 2007-03-07 2011-05-11 Concert Pharmaceuticals Inc. Deuterated piperazine derivatives as anti-anginal compounds

Similar Documents

Publication Publication Date Title
JP2010529994A5 (cg-RX-API-DMAC7.html)
JP2010530897A5 (cg-RX-API-DMAC7.html)
JP2010095546A5 (cg-RX-API-DMAC7.html)
JP2013032389A5 (cg-RX-API-DMAC7.html)
JP2013505929A5 (cg-RX-API-DMAC7.html)
JP2014500861A5 (cg-RX-API-DMAC7.html)
JP2011518833A5 (cg-RX-API-DMAC7.html)
JP2007302689A5 (cg-RX-API-DMAC7.html)
JP2012532883A5 (cg-RX-API-DMAC7.html)
JP2006526031A5 (cg-RX-API-DMAC7.html)
JP2009535462A5 (cg-RX-API-DMAC7.html)
JP2012092103A5 (cg-RX-API-DMAC7.html)
JP2015501820A5 (cg-RX-API-DMAC7.html)
HRP20221304T1 (hr) Kombinacija koja sadrži inhibitor mek i inhibitor b-raf
JP2010501534A5 (cg-RX-API-DMAC7.html)
IL190551A0 (en) Novel process for the preparation of acid chlorides
JP2013514980A5 (cg-RX-API-DMAC7.html)
JP2010540477A5 (cg-RX-API-DMAC7.html)
JP2010520214A5 (cg-RX-API-DMAC7.html)
JP2010079247A5 (cg-RX-API-DMAC7.html)
JP2012254971A5 (ja) カルバゾール化合物
JP2010534246A5 (cg-RX-API-DMAC7.html)
JP2010507590A5 (cg-RX-API-DMAC7.html)
JP2012518649A5 (cg-RX-API-DMAC7.html)
JP2012511558A5 (cg-RX-API-DMAC7.html)